| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424241100 | Escherichia (e.g., Escherichia coli, etc.) | 9 |
| 20080206284 | Agent For Treating Allergic or Hypersensitivity Condition - The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition and/or a hypersensitivity condition. | 08-28-2008 |
| 20080317784 | Immunogenic Compositions Containing Anthrax Antigen, Biodegradable Polymer Microparticles, And Polynucleotide-Containing Immunological Adjuvant - Immunogenic compositions and kits, as well as methods of stimulating immune responses and methods of immunization using the same. The compositions and kits comprise: (a) an antigen derived from | 12-25-2008 |
| 20090028909 | Intranasal Vaccine for Use Against Disease Caused by Enterotoxigenic Escherichia Coli - The disclosure relates to an intranasal peptide vaccine for use against infection caused by enterotoxigenic | 01-29-2009 |
| 20090035330 | Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant - The present invention provides a vaccine composition comprising the B-subunit of | 02-05-2009 |
| 20090202592 | CYTOLETHAL DISTENDING TOXIN, INHIBITION AND USE THEREOF - This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases. | 08-13-2009 |
| 20100047285 | ANTICANCER AGENTS USING VEROTOXIN VARIANTS - An attenuated verotoxin comprising a verotoxin A subunit amino acid sequence in which at least one of the amino acids at positions 167 to 172 and positions 202 to 207 from the N terminus is mutated; an attenuated verotoxin A subunit thereof; a complex of the A subunit with a ligand; an anticancer agent using the verotoxin, A subunit or ligand; a method for treating cancer; a gene that encodes the attenuated verotoxin or its A subunit; a gene therapy agent using the gene; and a gene therapy method. | 02-25-2010 |
| 20110236424 | TREATING ALLERGY WITH DETOXIFIED E. COLI HEAT-LABILE ENTEROTOXIN - A method for treating allergy with a pharmaceutical composition containing a detoxified | 09-29-2011 |
| 20120201853 | USE OF A HOLOTOXIN TO REDUCE ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION OF MISFOLDED PROTEINS - Provided is a use of a holotoxin to reduce endoplasmic reticulum-associated degradation (ERAD) of misfolded or abnormally folded proteins The holotoxin can thus be used in a method to treat diseases related to ERAD Examples of misfolded proteins that are degraded in the ER include the cystic fibrosis transmembrane conductance regulator (CFTR) delta F508 mutant protein, a misfolded mutant (G268V) of multi-drug resistance 1 (MDR1), and the glucocerebrosidase (GCC) enzyme in Gaucher's disease cells Examples of suitable holotoxins include ricin, shiga toxin, exotoxin A, plasmid-encoded toxin, cholera toxin, and verotoxin 1 (VT1) VT1 is also known as verotoxin A, shiga-like toxin 1, shiga-like toxin 1, or shiga toxin in type 1 A non-toxic inactive VT1 can also be used wherein crucial residues of the A subunit active site are mutated, for example, the mutations Y77S and E167Q | 08-09-2012 |
| 20140322274 | Therapeutic Agents - A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease. | 10-30-2014 |
